We are in the process of moving our store and on Wednesday, June 26 we suspended sales of "raw" cases until further notice. Our "cooked" cases will still be available up to the transition to the new store. All who have signed up for email from us will receive updates. If you are a bulk educational customer and need to purchase "raw" cases in the interim, please email us at case.access@yale.edu. Thank you for your patience!

First page of paper-based case study

Morgan Life Sciences

Cooked, Document

Vendor
Yale School of Management
Regular price
$9.50
Sale price
$9.50
Quantity must be 1 or more

(The following case is a fictional account, based on actual fact patterns from court cases)

Morgan Life Sciences Inc. was a biotechnology firm headquartered in Waltham, Massachusetts. Initially, it focused on generic and over-the-counter medications, which it manufactured and distributed to drugstores and supermarket chains. Morgan completed a successful initial public offering in 1994, but by the late 1990s, the generics market had become increasingly competitive. Morgan steadily lost ground as its larger, low-cost competitors pushed prices relentlessly downward.

The Morgan board promoted Wendy Shaw CEO in 1999. Recognizing that Morgan needed a major change of course, Shaw cut capital expenditures to the bone. Over the next five years the company built a decent stockpile of cash, even as its market share shrank. Meanwhile, she persuaded Morgan’s board that the company should invest in biotechnology.

Shaw, who held a doctorate in biochemistry, was charismatic and engaging. She quickly assembled a sophisticated, well-connected Scientific Advisory Board. In 2005, the Board made its first big move when it recommended hiring Andrei Petrozzi.

Published Date: 15/02/2008

Suggested Citation: Ben Flaumenhaft and Constance E. Bagley, "Morgan Life Sciences," Yale SOM Case 08-021, February 15, 2008

Keywords: Biotechnology, Science, Women in Leadership